Last reviewed · How we verify
Buprenorphine (Experimental)
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings.
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings. Used for Moderate to severe acute and chronic pain, Opioid use disorder (maintenance treatment).
At a glance
| Generic name | Buprenorphine (Experimental) |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management; Substance Use Disorder |
| Phase | FDA-approved |
Mechanism of action
Buprenorphine's partial agonist activity at the mu-opioid receptor produces a ceiling effect on respiratory depression, making it safer than full opioid agonists. It is used primarily for pain management and opioid use disorder treatment, where its high receptor binding affinity and long duration of action allow for once-daily or less frequent dosing while minimizing withdrawal symptoms and overdose risk.
Approved indications
- Moderate to severe acute and chronic pain
- Opioid use disorder (maintenance treatment)
Common side effects
- Constipation
- Nausea
- Headache
- Dizziness
- Sweating
- Respiratory depression
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People (EARLY_PHASE1)
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (PHASE2)
- Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial (NA)
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (PHASE2)
- A Bundled Intervention - Phase 2 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buprenorphine (Experimental) CI brief — competitive landscape report
- Buprenorphine (Experimental) updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI